<DOC>
	<DOCNO>NCT02795403</DOCNO>
	<brief_summary>The emergence hepatocellular carcinoma ( HCC ) prompt search thorough understand biology one major causative agent , hepatitis C virus ( HCV ) . HCV particles acquire via bud encapsidation cellular protein . There mount evidence several viral specie virion-bound protein prone involve either replication , budding/egress entry/release step viral cycle . Identifying target may yield ideal candidate gain insight dependence HCV upon restrict subset host protein , therefore provide refine set genetically stable target therapy . This project 's goal set adequate condition robust reproducible purification HCV virion clinical sample , follow identification HCV-bound host protein characterization function . Proteomics profile HCV particle purify clinical sample overlay protein identify characterize cell culture grow HCV particles post-doctoral training , use clinical biomarker discovery grade criterion . Targets identify sample set subject vitro investigation use HCV-replicating cell . Conventional biochemical imaging method use order : ( ) ascertain physical association HCV virion ; ( ii ) define modality interaction HCV protein ; ( iii ) decipher topology subcellular localization association HCV proteins virion ; ( iv ) quantitatively assess functional involvement particle budding , egress secretion infectivity . A candidate yield satisfactory result experiment disclose investigated level structural biology , collaborative research program .</brief_summary>
	<brief_title>HCV Virions Bound Proteins</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Adult &gt; 18 &lt; 60 year Infected HCV genotype 1 HCV antibody positive . positive viremia 6 month Viremia &gt; 106 IU / ml . nonresponders previous treatment without antiviral treatment 2 month . For control sample : Patients responder previous treatment without antiviral treatment 2 month . Patient receive received antiviral treatment within two month . patient againstindication blood sample 150 ml immunosuppressive therapy patient Patient liver disease hepatitis C. Patients cirrhosis . patient hepatocellular carcinoma . Patients one severe comorbidities define : Coinfection HIV HBV . hematological malignancy change aplasia Insulindependent diabetes dialyze chronic renal failure Heart failure Persons subject legal protection subject safeguard measure justice affiliate social security scheme beneficiary scheme Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HCV , liver</keyword>
</DOC>